Aurora, CONCT07318597Now EnrollingIRB Ready

Pulmonary Arterial Hypertension (PAH) Clinical Trial in Aurora, CO

Access cutting-edge pulmonary arterial hypertension (pah) treatment through this clinical trial at a research site in Aurora. Study-provided care at no cost to qualified participants.

Sponsored by Regeneron Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Aurora location

Preparing your pre-screening questions…

Expert Care in Aurora

Access pulmonary arterial hypertension (pah) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pulmonary arterial hypertension (pah) treatment provided free

Apply for This Aurora Location

Check if you qualify for this pulmonary arterial hypertension (pah) clinical trial in Aurora, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Aurora

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Aurora site if eligible
  4. 4Begin participation

About This Pulmonary Arterial Hypertension (PAH) Study in Aurora

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)

Sponsor: Regeneron Pharmaceuticals

Who Can Participate

Inclusion Criteria

Documented clinical diagnosis of PAH (Group 1 PH according to the 7th World Symposium on Pulmonary Hypertension (WSPH))
WHO functional class II or III (slight to marked limitation of functional status due to PAH)
Receiving background Standard Of Care (SOC) therapy for PAH on a stable dose and regimen, as determined by the investigator, as described in the protocol
PVR ≥400 dynes∙sec/cm\^5 (5 Wood units) based on Right Heart Catheterization (RHC) during the screening period
Has 6MWD ≥150 and ≤550 meters repeated twice during screening as described in the protocol Key

Exclusion Criteria

Has Group 2 (PH associated with left heart disease), Group 3 (PH associated with lung diseases and/or hypoxia), Group 4 (PH associated with pulmonary artery obstructions), or Group 5 (PH with unclear and/or multifactorial mechanisms) PH according to the 7th WSPH
Pulmonary Arterial Wedge Pressure (PAWP) \>15 mm Hg by RHC during the screening period
History of left-sided heart disease and/or clinically significant cardiac disease, as described in the protocol
Obstructive lung disease defined as Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity \<0.7 and FEV1 \<70% of the predicted value as described in the protocol
Evidence of interstitial lung disease as defined in the protocol
Evidence of chronic thromboembolic pulmonary disease or acute pulmonary embolism as described in the protocol
Participants requiring anticoagulation and/or antiplatelet therapy for an underlying medical condition as described in the protocol
Has any history of intracranial bleeding or any history of elevated intracranial pressure
Has any history of bleeding meeting criteria as described in the protocol Note: Other protocol-defined Inclusion/ Exclusion criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Aurora?

Yes, this clinical trial (NCT07318597) has an active research site in Aurora, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pulmonary Arterial Hypertension (PAH) Treatment Options in Aurora, CO

If you're searching for pulmonary arterial hypertension (pah) treatment options in Aurora, CO, this clinical trial (NCT07318597) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Aurora research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pulmonary arterial hypertension (pah) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pulmonary arterial hypertension (pah) clinical trials near you to find additional studies recruiting in your area.

More Hypertension Trials in Aurora, CO

See all hypertension clinical trials recruiting in Aurora — not just this study.

Browse Hypertension Trials in Aurora →

Browse More Trials by Condition

Hypertension TrialsPulmonary Embolism TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Aurora?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Aurora, CO